Doses - DOXORUBICIN HCL
For maximum effect, doxorubicin is most commonly employed as part of a multi-drugprotocol. For more information, refer to the protocols found in the appendix or other protocolsfound in numerous references, including: Handbook of Small Animal Practice (Stann 1988b);
Handbook of Small Animal Therapeutics (Rosenthal 1985); Current Veterinary Therapy X: Small
Animal Practice (Helfand 1989), (Matus 1989); and Textbook of Veterinary Internal Medicine, 3rd
Edition (Couto 1989a).Dogs:
For susceptible neoplasms:
a) 30 mg/m2 IV or intracavitary every 21 days or 10 mg/m2 IV every 7 days. Maximumcumulative dose: 240 mg/m2. Pretreat with antihistamine. (Thompson 1989a)
b) 30 mg/m2 IV every 21 days. Maximum cumulative dose: 200 mg/m2. (Macy 1986)
c) 30 mg/m2 IV every 21 days. Maximum cumulative dose: 240 mg/m2. (MacEwen and Rosenthal 1989)Cats:
For susceptible neoplasms:
a) For lymphosarcoma, carcinomas, sarcomas, myeloma, and leukemias: 20 - 30 mg/m2every 3-4 weeks. (Couto 1989b)
Monitoring Parameters -1) Efficacy 2) Toxicity a) CBC with platelets b) Dogs with pre-existing heart disease should be monitored with regular ECG's (insensitiveto early toxic changes caused doxorubicin) and/or echocardiogram
c) Evaluate hepatic function prior to therapy
d) Urinalyses and serum creatinine/BUN in cats
Client Information - Clients must be briefed on the possibilities of severe toxicity developing from this drug, including drug-related mortality. Clients should contact the veterinarian should the patient exhibit any symptoms of profound depression, abnormal bleeding (including bloody diarrhea) and/or bruising.
Doxorubicin may cause urine to be colored orange to red for 1-2 days after dosing. Mild anorexia and occasional vomiting are commonly seen 2-5 days post-therapy. Avoid handling urine of treated dogs.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None.
Doxorubicin HCl Injection 2 mg/ml in 5, 10, 20, 25 ml & 100 ml (preservative free) vials;
Adriamycin PFS® (Pharmacia); Doxorubicin HCl® (Cetus); Doxil® (Sequus); (Rx)
Handbook of Small Animal Therapeutics (Rosenthal 1985); Current Veterinary Therapy X: Small
Animal Practice (Helfand 1989), (Matus 1989); and Textbook of Veterinary Internal Medicine, 3rd
Edition (Couto 1989a).
Dogs: 
For susceptible neoplasms: a) 30 mg/m2 IV or intracavitary every 21 days or 10 mg/m2 IV every 7 days. Maximumcumulative dose: 240 mg/m2. Pretreat with antihistamine. (Thompson 1989a)
b) 30 mg/m2 IV every 21 days. Maximum cumulative dose: 200 mg/m2. (Macy 1986)
c) 30 mg/m2 IV every 21 days. Maximum cumulative dose: 240 mg/m2. (MacEwen and Rosenthal 1989)
Cats: 
For susceptible neoplasms: a) For lymphosarcoma, carcinomas, sarcomas, myeloma, and leukemias: 20 - 30 mg/m2every 3-4 weeks. (Couto 1989b)
Monitoring Parameters -
c) Evaluate hepatic function prior to therapy
d) Urinalyses and serum creatinine/BUN in cats
Client Information - Clients must be briefed on the possibilities of severe toxicity developing from this drug, including drug-related mortality. Clients should contact the veterinarian should the patient exhibit any symptoms of profound depression, abnormal bleeding (including bloody diarrhea) and/or bruising.
Doxorubicin may cause urine to be colored orange to red for 1-2 days after dosing. Mild anorexia and occasional vomiting are commonly seen 2-5 days post-therapy. Avoid handling urine of treated dogs.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None.
Human-Approved Products:
Doxorubicin HCl Lyophilized Powder for Injection 10 mg, 20 mg, 50 mg, 100 mg, & 150 mg vials; Adriamycin RDF® (Pharmacia); Doxorubicin HCL® (Cetus), Adriamycin PFS® (Pharmacia); Rubex® (Bristol-Myers Oncology); generic; (Rx). Reconstitute with appropriate amount of 0.9% sodium chloride for final concentration of 2 mg/ml.Doxorubicin HCl Injection 2 mg/ml in 5, 10, 20, 25 ml & 100 ml (preservative free) vials;
Adriamycin PFS® (Pharmacia); Doxorubicin HCl® (Cetus); Doxil® (Sequus); (Rx)